News

New cancer target draws €259m
Enlarge image

BusinessUK

New cancer target draws €259m

11.12.2012 - British pharma GlaxoSmithKline fosters its transatlantic ties. Texas-based MD Anderson will receive €259m for a cancer immune therapy programme.

GlaxoSmithKline (GSK) secured a promising cancer immune therapy programme by collaborating with University of Texas MD Anderson from Houston (US). The deal, which allots GSK worldwide exclusive rights, was been made public on 7 December. In total, the pharma company could pay more than €259m in upfront and milestone payments, excluding the royalties of possible therapeutic antibody sales.

The programme in question has been established by former MD Anderson professor Yong-Jun Liu who is now working at the Baylor Research Institute in Dallas. Liu found that an activation of the T cell receptor OX40 (CD134) on the surface of dendritic cells improves the chances of an immune attack mediated by these cells: "T cell recognition of a tumour antigen is not enough to activate the T cells against cancer cells, they need a secondary signal to tell them “that antigen you have is a bad thing, you have to attack,'“ Liu said. Hence, he and his team screened for antibodies that could mimic the natural activator OX40L, which enables amplification of Th2 cell differentiation upon binding to its receptor. Right now the candidates have been boiled down to half a dozen. The collaboration with GSK in this late preclinical stage comes as no surprise for Liu: "It is gratifying to see this important step towards translating a basic science discovery into a potential new therapy that can proceed to clinical trial.“

The agreement between academia and economy is the first pact for MD Anderson’s new Institute for Applied Cancer Science (IACS). This institute is one of several projects of the recently launched ‚Moon Shot Program’ that tries to advance discoveries from basic sciences into the clinic. Dubbed as the „nation’s No. 1 hospital for cancer care“, MD Anderson thinks that „the end of cancer is closer than you think.“ Other cancer types included in the Moon Shots Program are breast and ovarian cancers, leukaemia (AML/MDS as well as CLL), lung cancer, melanoma and prostate cancer.

It is not the first time that a company aims to target OX40. The human MAB oxelumab targets not the receptor but its ligand OX40L. After Phase II trails in allergic asthma patients failed, Roche's US subsidiary Genentech terminated the development of oxelumab (huMAb OX40L) with Danish Genmab in Q2/2011.

© eurobiotechnews.eu/ml

http://www.european-biotechnology-news.com/news/news/2012-04/new-cancer-drug-target-draws-eur259m.html

FinancingBelgium

20.07.2016 Belgian molecular diagnostics company Biocartis Group NV has raised €55m and will use the funds mainly to expand manufacturing capacities for its PCR-based molecular diagnostics system Idylla.

Stock marketsFranceEU

19.07.2016 It is Europe’s first gene therapy company to float on Euronext: Gensight raised €40m in its IPO. And it is not the only French company that has taken the leap in an uncertain market climate – Alzheimer’s expert Pharnext also went public.

ResearchUK

18.07.2016 When NASA blasted off to the International Space Station on Monday morning, it had UK tech on board. A miniature DNA sequencer from Oxford Nanopore will be used to keep an eye on the ISS atmosphere – and may even analyse alien DNA one day.

M&AUKSwitzerland

13.07.2016 Cell Medica has acquired Swiss antibody specialist Delenex Therapeutics. The deal nets the British cellular therapeutics developer Delenex’ proprietory antibody fragment platform Pentrabody.

R&DAustriaFrance

12.07.2016 Vienna-based vaccine specialist Themis Bioscience GmbH has secured broad access to a promising virus vaccine vector tech by extending its license agreement with French Institut Pasteur. Its goal: to develop a Zika vaccine.

M&AFranceEU

07.07.2016 Californian biopharma Medivation has agreed to confidential negotiations with its suitors, in particular the French pharmaceutical company Sanofi, which aggressively has buffeted the cancer therapy specialist for months.

Prenatal DiagnosticsEUUK

06.07.2016 The European Commission started an investigation into Illumina’s and Sequenom’s 2014 patent agreement, UK-competitor Premaitha Health said. The two US companies had agreed to pool their Noninvasive Prenatal Testing IP.

GenericsSpainGermanyEU

04.07.2016 Cinfa Biotech is shuffling for position on the lucrative biosimilar market. The Spanish-German company has published positive results in a study for a pegfilgrastim copycat with 172 healthy volunteers in Germany.

Drug discoveryUKSwitzerland

30.06.2016 UK’s Heptares Therapeutics and Paul Scherrer Institute spinoff leadXpro will collaborate to find new approaches for the determination of high-res X-ray structures of G protein-coupled receptors to find new drugs.

Nuclear medicineNorwayFrance

28.06.2016 Nordic Nanovector has teamed up with Areva Med to develop a treatment for leukaemia. The compound in question is a lead-212 conjugated anti-CD37 antibody.

Quick news provided by GlobeNewswire

View more stock news

Events

All Events

Partner-Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • MOLOGEN (D)1.50 EUR12.78%
  • BIOCARTIS GROUP NV (B)7.57 EUR7.53%
  • SWEDISH ORPHAN BIOVITRUM (S)13.11 USD6.59%

FLOP

  • NICOX (F)11.57 EUR-8.61%
  • KAROLINSKA (S)7.55 SEK-4.43%
  • AB SCIENCE (F)14.20 EUR-4.05%

TOP

  • PROTHENA PLC (IE)53.17 USD49.9%
  • FLAMEL TECHNOLOGIES (F)12.49 USD32.2%
  • TIGENIX (B)1.05 EUR26.5%

FLOP

  • MOLOGEN (D)1.50 EUR-40.0%
  • EVOCUTIS (UK)0.04 GBP-20.0%
  • SANTHERA (CH)56.75 CHF-18.9%

TOP

  • KARO BIO (S)28.70 SEK1705.0%
  • NICOX (F)11.57 EUR493.3%
  • SAREUM HOLDINGS (UK)0.64 GBP166.7%

FLOP

  • BB BIOTECH (D)45.22 EUR-84.5%
  • NEUROVIVE PHARMACEUTICAL AB (S)4.64 SEK-79.3%
  • EVOCUTIS (UK)0.04 GBP-76.5%

No liability assumed, Date: 23.07.2016